On-Demand Webcasts: IAS–USA Virtual Update on HIV: Antiretroviral Therapy, New ART Drugs and Strategies, and the Intersection of COVID-19 and HIV

On-Demand Webcasts: IAS–USA Virtual Update on HIV: Antiretroviral Therapy, New ART Drugs and Strategies, and the Intersection of COVID-19 and HIV

Release date: June 29, 2020
Expiration date: June 29, 2021
No longer available for CME credit

Program Description

This new, first virtual CME course from the IAS–USA combines planned presentations from the postponed courses, including Los Angeles and San Francisco HIV update courses. We have shortened the program and narrowed down the topics to the key issues on which most of you are likely focusing, as we know it is difficult for you to dedicate an entire day to participate in a virtual course during this time. We will cover other topics related to comorbidities, issues in aging, and so on in our COW webinar programming, which you can access live or on demand.

Although scheduled to accommodate West Coast HIV clinicians, the course is open to all.

We are doing our best to adapt during this uncertain time and provide you with timely updates on key issues in formats you can easily access. We appreciate any feedback you have for us, and we thank you for your patience.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented virtually through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

• Describe the most current data on available new antiretroviral drugs and approaches
• Identify situations in which the choice of antiretroviral regimens should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Initiate and monitor HIV prevention intervention strategies, including the use of preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
• Describe the status of research into treatment and a vaccine for COVID-19
• Describe the current best understanding of the impact of COVID-19 on HIV
• Describe the best practices for preventing the spread of infectious diseases

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.